Medisyn is committed to creating superior products for important medical needs. Using Forward Engineering™, we have rapidly advanced a broad portfolio of preclinical candidates that target major therapeutic categories including cancer, Alzheimer's disease, infectious disease, pain, inflammation and acute radiation syndrome. Medisyn can also deliver custom discovery projects based on your specific requirements.
Unmet Need - Cancer is the second leading cause of death in the U.S. According to the American Cancer Society, approximately 1 million new cases of cancer are diagnosed each year. The National Cancer Institute estimates annual direct medical costs for cancer treatment to be $40 billion in the United States.
Our Approach - Medisyn has discovered a series of potent inhibitors of PKC, RAS and RTKI pathways. These compounds display activity across a wide range of tumor types with potencies superior to current clinical stage compounds.
Non small Cell Lung (NSCLC)
MT103 is a novel drug with potential application for treatment of PKC modulated cancers. In studies, MT103 preferentially inhibited the proliferation of NSCLC cell lines and induced apoptosis. MT103 was well tolerated in in vivo studies and compared favorably against other cancer treatment benchmarks .
MT477 is a novel quinoline with potential application for treatment of Ras-mutated cancers. In recent in vivo studies, MT477 preferentially inhibited the proliferation of K-ras-mutated human pulmonary and pancreatic adenocarcinoma cell lines, induced apoptosis, is associated with caspase-3 activation, and induced sub-G1 cell-cycle arrest. MT477 is active in Ras-mutated cancers as well as non-Ras mutated cancers and could be developed extensively as an anticancer drug lead.
MT062 is a novel lead with potential application for treatment of RTKI pathway cancers. In studies, MT062 was found to be a selective and potent EGFR inhibitor.
Unmet Need - Alzheimer's Disease is a form of dementia and is incurable, degenerative, and terminal. There are 26 million cases of Alzheimer's Disease today, and the number may quadruple within the next 50 years. It is fast becoming a global health issue. Currently, the disease is only able to be managed. Novel drugs are needed to cure the disease.
Our Approach - Medisyn has partnered with the Mount Sinai School of Medisyn to leverage their cutting edge research by providing Medisyn with experimental data to build models for useful activity against Alzheimer's disease. Medisyn has delivered compounds that have quickly advanced through in vitro screening to in vivo studies with a high degree of bioactive specificity based on the researchers needs.
- Selective Aβ1-40 and Aβ1-42 lowering agents and Anti-aggregation agents
One hypothesis to explain the cause of the disease is the initiation of large-scale aggregation of amyloid plaques leading to generalized neuroinflammation. Models have been created to identify selective amyloid-beta lowering agents as well as anti-aggregation agents.
Unmet Need - Neuropathic pain is a chronic condition usually associated with abnormal sensations which can be as severe as debilitating pain. It cannot be explained by a single disease process or a single specific location of damage and therefore is difficult to treat. Only 40-60% of patients find partial relief using common treatments.
Our Approach - Medisyn has partnered with MD Biosciences to find new neuropathic pain agents.
- GABA-mimetics and GABA B receptor agonists
- GABA mimetics increase the amount of GABA in the body and has a calming, anti-anxiety, and anti-convulsive effect. These effects are also beneficial to the perception of pain.
- GABA B receptor agonists are associated with the neurological processes related to ethanol and generate a sedative effect.
Unmet Need - Inflammation has been implicated in myalgia, arthralgia, tendonitis, and dental/bone irritation and reduction of inflammation resolves the corresponding pain condition. Anti-inflammatory agents like non-steroidal anti-inflammatory drugs (NSAIDS) are based on cyclooxygenase-1 (COX-1)/cyclooxygenase-2 (COX-2) inhibition and result in gastrointestinal (GI) distress. Hence, selective COX-2 inhibitors were developed yet the cardiovascular protective effects of NSAIDs mediated through COX-1 inhibition are lost. Emerging data regarding the role of the 5-lipoxygenase (5-LO) pathway suggests its inhibition indirectly reduces TNF-a expression. Considering the influence of COX-2/5-LO pathway, drugs able to block both pathways (dual inhibitors), should present a superior anti-inflammatory profile than individual selective COX-2/5-LOX inhibitors.
Our Approach - Medisyn’s approach is to use molecular topology (MT) to identify novel anti-inflammatory agents without adverse effects to the GI system or increase in cardiovascular risks based on dual inhibition of COX-2/5-LO activity. Separate individual inhibitory (COX-1, COX-2, 5-LO and COX-2/5-LO) activity profiles were created to define the molecular topological signature responsible for dual inhibition of COX-2/5-LO activity with minimal COX-1 inhibition since it is unclear the extent to which COX-1 inhibition is required to minimize cardiovascular risk.
- Multiple compounds in new chemical classes inhibiting both COX-2 and 5-LO
Acute Radiation Syndrome (ARS)
Unmet Need - Today there is a lack of effective agents that are easily deployed and administered for Acute Radiation Syndrome. The threat of "dirty bombs" and other radiological events has increased the need to find effective treatments and prophylaxes.
Our Approach - Medisyn has partnered with Humanetics to leverage their research efforts and experimental data to build in silico predictive models for identification of novel radioprotective and radiotherapeutic natural compounds.
- Radioprotectants help the body protect from tissue damage as a result of radiation exposure.
- Radiotherapeutics help stimulate the body to regenerate cells damaged by radiation exposure.